Jefferies Likes Early Iclusig Sales Data for ARIAD Pharmaceuticals (ARIA)
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Goldman Sachs Starts ARIAD Pharmaceuticals (ARIA) at Neutral
March 28, 2013 7:26 AM EDTGoldman Sachs initiates coverage on ARIAD Pharmaceuticals (NASDAQ: ARIA) with a Neutral. PT $20.00.
With shares up 55% since reporting the initial pivotal data for Iclusig on December 11, 2011, and valuation at a premium to peers, they see current valuation as fair.
For an... More